Publicly available stock market data

HilleVax Shares Plunge 88.6% to $1.60 After Norovirus Vaccine Fails in Mid-Stage Trial

Jul 8, 2024, 01:50 PM

HilleVax reported that its NEST-IN1 Phase 2b clinical study of HIL-214 in infants did not meet its primary or secondary efficacy endpoints. As a result, the company will discontinue further development of HIL-214 in infants. Following this announcement, HilleVax's stock plummeted, dropping 88.6% to $1.60 in premarket trade, with an 86.3% decline premarket. The failed trial aimed to prevent gastroenteritis caused by norovirus, specifically acute gastroenteritis. The significant decline in stock value reflects investor disappointment in the biotech company's sole clinical candidate's failure.